Cargando…

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls

Detalles Bibliográficos
Autores principales:	Scheerans, Christian, Blunck, Martin, Mueck, Wolfgang, Frey, Reiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363258/ http://dx.doi.org/10.1186/1471-2210-11-S1-P61

Ejemplares similares

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009)

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
por: Irvine, Jennifer C., et al.
Publicado: (2012)

Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat
por: Kollau, Alexander, et al.
Publicado: (2017)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs
por: Næsheim, Torvind, et al.
Publicado: (2020)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
por: Krieg, Thomas, et al.
Publicado: (2009)

The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
por: Mátyás, Csaba, et al.
Publicado: (2015)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
por: Boettcher, Michael, et al.
Publicado: (2020)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains
por: Rehan Khalid, Rana, et al.
Publicado: (2018)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model
por: Ataei Ataabadi, Ehsan, et al.
Publicado: (2022)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

A new small molecule inhibitor of soluble guanylate cyclase
por: Mota, Filipa, et al.
Publicado: (2015)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Activation mechanism of human soluble guanylate cyclase by stimulators and activators
por: Liu, Rui, et al.
Publicado: (2021)

Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF-β Pathway
por: Fleischmann, Daniel, et al.
Publicado: (2021)

Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
por: Miller, Thomas W, et al.
Publicado: (2009)

Stimulators and Activators of Soluble Guanylate Cyclase: Review and Potential Therapeutic Indications
por: Nossaman, Bobby, et al.
Publicado: (2012)

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
por: Rogers, Natasha M., et al.
Publicado: (2014)

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma
por: Buys, Emmanuel S., et al.
Publicado: (2014)

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development
por: Gileadi, Opher
Publicado: (2014)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Khalid, Rana Rehan, et al.
Publicado: (2020)

The effects of the soluble guanylate cyclase stimulator riociguat on memory performance in healthy volunteers with a biperiden-induced memory impairment
por: Borghans, Laura G. J. M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qsen5um4v0q3icgqd6upf60fop